X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Indoco Remedies with FUTURE VENTURES - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

INDOCO REMEDIES vs FUTURE CONSUMER - Comparison Results

INDOCO REMEDIES    Change

Indoco Remedies is engaged in the manufacturing and marketing of formulations and active pharmaceutical ingredients (APIs) for domestic as well as the international markets. The company's focus areas include anti-infective, respiratory, anti-diabetic... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    INDOCO REMEDIES FUTURE CONSUMER INDOCO REMEDIES/
FUTURE CONSUMER
 
P/E (TTM) x 23.1 -70.7 - View Chart
P/BV x 2.7 8.5 32.2% View Chart
Dividend Yield % 0.8 0.0 -  

Financials

 INDOCO REMEDIES   FUTURE CONSUMER
EQUITY SHARE DATA
    INDOCO REMEDIES
Mar-17
FUTURE CONSUMER
Mar-14
INDOCO REMEDIES/
FUTURE CONSUMER
5-Yr Chart
Click to enlarge
High Rs36011 3,400.0%   
Low Rs2495 5,535.6%   
Sales per share (Unadj.) Rs119.05.8 2,036.6%  
Earnings per share (Unadj.) Rs8.40 -19,257.6%  
Cash flow per share (Unadj.) Rs15.20.2 7,518.5%  
Dividends per share (Unadj.) Rs1.600-  
Dividend yield (eoy) %0.50-  
Book value per share (Unadj.) Rs70.75.0 1,402.3%  
Shares outstanding (eoy) m92.151,597.98 5.8%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x2.61.3 198.2%   
Avg P/E ratio x36.4-173.8 -21.0%  
P/CF ratio (eoy) x20.037.3 53.7%  
Price / Book Value ratio x4.31.5 287.8%  
Dividend payout %19.10-   
Avg Mkt Cap Rs m28,08312,065 232.8%   
No. of employees `0006.0NA-   
Total wages/salary Rs m2,167677 319.9%   
Avg. sales/employee Rs Th1,817.0NM-  
Avg. wages/employee Rs Th359.0NM-  
Avg. net profit/employee Rs Th127.7NM-  
INCOME DATA
Net Sales Rs m10,9689,339 117.4%  
Other income Rs m4029 137.4%   
Total revenues Rs m11,0079,368 117.5%   
Gross profit Rs m1,565257 607.8%  
Depreciation Rs m633393 161.0%   
Interest Rs m6252 119.0%   
Profit before tax Rs m909-159 -571.9%   
Minority Interest Rs m077 0.0%   
Prior Period Items Rs m04 0.0%   
Extraordinary Inc (Exp) Rs m03 0.0%   
Tax Rs m139-6 -2,350.8%   
Profit after tax Rs m771-69 -1,110.5%  
Gross profit margin %14.32.8 517.5%  
Effective tax rate %15.33.7 411.0%   
Net profit margin %7.0-0.7 -945.6%  
BALANCE SHEET DATA
Current assets Rs m5,7255,413 105.8%   
Current liabilities Rs m5,4542,336 233.5%   
Net working cap to sales %2.532.9 7.5%  
Current ratio x1.02.3 45.3%  
Inventory Days Days6241 152.4%  
Debtors Days Days7243 167.7%  
Net fixed assets Rs m5,3073,772 140.7%   
Share capital Rs m1849,588 1.9%   
"Free" reserves Rs m6,331-1,667 -379.7%   
Net worth Rs m6,5168,057 80.9%   
Long term debt Rs m1,3231 165,387.5%   
Total assets Rs m11,97010,594 113.0%  
Interest coverage x15.6-2.0 -764.6%   
Debt to equity ratio x0.20 204,513.9%  
Sales to assets ratio x0.90.9 103.9%   
Return on assets %7.0-0.2 -4,285.3%  
Return on equity %11.8-0.9 -1,373.2%  
Return on capital %12.4-0.3 -4,323.2%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m4,5070-   
Fx outflow Rs m1,1410 380,466.7%   
Net fx Rs m3,3660 -1,121,833.3%   
CASH FLOW
From Operations Rs m886-791 -112.0%  
From Investments Rs m-1,706829 -205.8%  
From Financial Activity Rs m1,316-62 -2,125.5%  
Net Cashflow Rs m497-24 -2,059.7%  

Share Holding

Indian Promoters % 59.2 41.7 142.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 12.5 0.0 -  
FIIs % 6.0 18.7 32.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 22.4 39.5 56.7%  
Shareholders   12,805 27,455 46.6%  
Pledged promoter(s) holding % 0.0 71.3 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare INDOCO REMEDIES With:   BAJAJ FINANCE  MIC ELECTRONICS  COMMEX TECHNOLOGY  THOMAS COOK INDIA  REDINGTON (INDIA)  



Today's Market

Weak Finish to the Week Post Vishal Sikka's Exit as CEO of Infosys(Closing)

Share markets in India witnessed selling pressure, led by slump in shares of Infosys Ltd. after Vishal Sikka resigned as chief executive officer of the country's second-largest software services exporter.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

INDOCO REMEDIES SHARE PRICE


Aug 18, 2017 (Close)

TRACK INDOCO REMEDIES

  • Track your investment in INDOCO REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON INDOCO REMEDIES

INDOCO REMEDIES 8-QTR ANALYSIS

COMPARE INDOCO REMEDIES WITH

MARKET STATS